Europe is leading a strategic transition towards personalized and precision medicine, driven by the need to improve outcomes, reduce adverse effects, and increase efficiency in healthcare. In this context, nanomedicine is emerging as a key enabler, offering tools for precise, safe, and scalable delivery of therapeutic agents tailored to the unique profiles of patients.
The European Agenda for personalized medicine
The European Union is actively reshaping its healthcare strategy through a clear pivot toward personalized and precision medicine. This shift responds not only to clinical needs—such as improving treatment efficacy and reducing adverse effects—but also to systemic goals: making healthcare more sustainable, data-driven, and citizen-centered.
Over the past years, the EU has placed precision health at the core of several strategic frameworks:
- Horizon Europe – Cluster 1 (Health): funding R&D for diagnostics, therapies, and technologies tailored to individual patient profiles.
- The European Health Data Space (EHDS): enabling secure, interoperable sharing of health data to fuel Artificial Intelligence (AI) models, digital twins, and biomarker-based treatments.
- The 1+ Million Genomes Initiative: supporting cross-border genomic sequencing to improve diagnostics and treatments for cancer, rare diseases, and complex conditions.
- The EU Mission on Cancer: fostering early detection and personalized treatment strategies based on molecular profiling and omics.
These programs reflect a broader move toward mission-oriented innovation in healthcare, tackling complex challenges through coordinated science, infrastructure, and policy efforts.
However, precision medicine doesn’t end with data. The growing focus on Advanced Therapy Medicinal Products (ATMPs), such as gene therapies, CAR-T cells, and mRNA-based treatments, has revealed a technological bottleneck: the need for delivery systems capable of translating molecular insights into targeted therapeutic action.
This is where nanomedicine becomes indispensable.
Nanomedicine: the missing link in the precision chain
While omics and AI provide information, nanotechnology translates it into action. Nanomedicine delivers the functional layer that enables precision treatments to reach the right cells, at the right time, with the right dose.
Its core contributions include:
- Targeted delivery: Nanocarriers such as lipid nanoparticles can selectively reach diseased cells, minimizing systemic toxicity.
- Modular platforms: Adaptable to different nucleic acids, small molecules, or protein cargoes, ideal for personalized regimens.
- Combination therapies: Co-delivery of synergistic agents (e.g., mRNA + immunomodulators) to address complex pathologies.
- Theranostics: Nanosystems combining diagnostics and therapy enable real-time monitoring and treatment adjustment.
The European Technology Platform on Nanomedicine (ETPN) has consistently emphasized the role of nanotechnology in achieving EU health goals, especially in enabling equitable access to advanced therapies and supporting the industrial translation of precision tools.
DIVERSA’s contribution to Europe’s Precision Health Goals
At DIVERSA, we are deeply aligned with Europe’s vision for precision, safe, and scalable health innovation. Our work focuses on biodegradable lipid nanoparticles engineered for:
- Targeted delivery of nucleic acids (e.g., mRNA, plasmid DNA, CRISPR tools),
- Controlled release of therapeutic payloads, and
- Customizable formulations adapted to specific pathologies or patient groups.
These nanocarriers are being applied in projects related to gene editing, cell therapy, and immune modulation, advancing therapies that are more personalized, sustainable, and clinically actionable.
By building modular and GMP-ready platforms, DIVERSA contributes to the scalability and industrial feasibility of personalized nanomedicine, bridging the gap between policy ambition and real-world implementation.
Towards as new paradigm in healthcare
Europe’s transition toward precision health depends on the ability to translate molecular data into targeted, effective interventions. Nanomedicine offers the physical and functional interface that connects digital diagnostics with biological therapies.
To fully unlock its potential, cross-disciplinary collaboration is essential: integrating biotech, materials science, clinical research, and regulatory frameworks under a unified European vision.
With the right policy support and investment, nanotechnology will be at the core of future-ready, equitable, and individualized medicine in Europe—delivering not only innovation, but better lives.
Visit www.diversatechnologies.com or send an email to info@diversatechnologies.com to explore our solutions.
References
Internal References
- How nanotechnology is shaping the future of personalized medicine
- Overcoming regulatory hurdles in clinical translation of nanomedicine
- From bench to bedside: accelerating clinical translation with lipid nanoparticles
- Personalized nanomedicine at the bedside: the next frontier in RNA-Nanoparticle Therapies
External References
- Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 6(12), 1078-1094. doi.org/10.1038/s41578-021-00358-0
- Karmaker, S., Rosales, P. D., Tirumuruhan, B., Viravalli, A., & Boehnke, N. (2025). More than a delivery system: the evolving role of lipid-based nanoparticles. Nanoscale, 17(19), 11864-11893. doi.org/10.1039/D4NR04508D
- Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F., Zhang, Z., … & Huang, W. (2022). Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics, 14(12), 2682. doi.org/10.3390/pharmaceutics14122682
- European Technology Platform on Nanomedicine
